CSL ranked fourth on the Health Industry list, from a total of more than 750 organisations nominated in all sectors across Australia and New Zealand. MELBOURNE, 27, April: Today, CSL is honoured...

With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectors KING OF PRUSSIA, Pa., 2 March 2022 – Forbes Magazine has named global biotechnology leader...

CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd. MELBOURNE, Australia and ST. GALLEN, Switzerland. CSL Behring AG, Berne,...

Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron...

Melbourne, 14 December 2021 – CSL Limited (ASX:CSL) and its vaccine business, Seqirus, today reaffirms a strong commitment to accelerating its proprietary next-generation self-amplifying mRNA...

Through the StartX partnership, CSL will access an ecosystem of early stage biotech, medtech and digital healthcare ventures, exploring opportunities to collaborate around disruptive technologies...

- CSL, WEHI and The University of Melbourne have secured funding to join forces and create an incubator and commercial wet lab space for biotech start-up companies - The project partners are...

Faster treatments for future pandemics (Brisbane) Investigating the DNA factory in our bodies that makes everything (Melbourne) MELBOURNE and BRISBANE; October 27, 2021: Two Australian scientists...

MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021: Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a...

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022 Melbourne, Australia: CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19...

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...

CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary...

New Patent Box policy will benefit domestic commercialisation of medical research Melbourne, Australia: CSL welcomes the Federal Government’s Budget commitment to introduce a Patent Box that...

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...

CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and...

CSL continues to provide medicines to patients around the world. Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide...

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 CSL and AstraZeneca have agreed for CSL to manufacture approximately 50...

Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling. The release follows the completion of...

CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards...

24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin January 31, 2021, Melbourne: CSL Behring Australia, a subsidiary of CSL Limited, today announced that...

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne. November 8, 2020, Melbourne — CSL Limited (ASX:CSL) CSL today confirmed it will commence...